Volume 10, Issue 6, June – 2025 International Journal of Innovative Science and Research Technology
ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

Unmasking Guillain-Barre Syndrome: From Triggers to Treatment

Shaik Parveen[1]; D. Gowthami[2]; P. Sanjana[3]; N. Sharanya[4*]

[1,2,3,4]Malla Reddy College of Pharmacy Maisammaguda, Dhulapally, Kompally (PO), Secunderabad-500100, India

Corresponding Author: N. Sharanya[4*]

Publication Date: 2025/06/13

Abstract: Guillain-Barre Syndrome (GBS) is rare yet serious acute immune-mediated polyneuropathy impacting peripheral nervous system, often occurring after an infection. It usually manifests as rapidly advancing, symmetrical weakness in the limbs, areflexia, and sensory disturbances of varying degrees. GBS encompasses various clinical forms, such as Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Acute Motor Axonal Neuropathy (AMAN), as well as Miller Fisher Syndrome (MFS). From an epidemiological perspective, the global incidence of GBS is 0.89-1.89 cases per 100,000 person-years, with higher frequency observed among older adults and males. Infections, especially Epstein-Barr virus, cytomegalovirus, Campylobacter jejuni, as well as Zika virus, correlate with regional and seasonal variations. The pathogenesis includes molecular mimicry, where antibodies cross-react with gangliosides on peripheral nerves, leading to demyelination or axonal degeneration. The diagnosis is mainly clinical, corroborated by Nerve conduction studies (NCS), as well as analysis of Cerebrospinal fluid (CSF) that demonstrates albuminocytological dissociation. GBS constitutes a medical emergency because of the dangers of respiratory failure, autonomic dysfunction, and cranial nerve involvement. During the acute phase, supportive care such as respiratory monitoring, Deep-vein thrombosis (DVT) prophylaxis, and nutritional support is essential. During recovery, rehabilitation plays an important part, centring on the restoration of motor function, complication prevention, and enhancement of quality of life. Although the majority of patients recover, a subset continues to experience long-term disability and fatigue. It is essential to identify early, treat promptly, and manage with a multidisciplinary approach in order to achieve optimal outcomes. To enhance patient care and reduce long-term complications, ongoing investigation into immunopathogenesis and treatment approaches is essential.

Keywords: *Acute Inflammatory Demyelinating Polyradiculoneuropathy, Acute Motor Axonal Neuropathy, Miller Fisher Syndrome, Nerve Conduction Studies, Deep Vein Thrombosis Prophylaxis.*

How to Cite: Shaik Parveen; D. Gowthami; P. Sanjana; N. Sharanya (2025) Unmasking Guillain-Barre Syndrome: From Triggers to Treatment. *International Journal of Innovative Science and Research Technology*, 10(6), 330-341. https://doi.org/10.38124/ijisrt/25jun078

I. INTRODUCTION

Guillain-Barre Syndrome (GBS) is rare and rapidly developing immune-mediated condition affecting peripheral nervous system, frequently occurring after an infectious disease. The syndrome mainly manifests as muscle weakness that develops quickly, tingling sensations, and areflexia. It typically progresses symmetrically, often starting in lower limbs, as well as moving up to involve upper limbs, as well as facial muscles [1]. Due to its potential to lead to life-threatening complications like respiratory failure, autonomic dysfunction, and bulbar weakness, it is regarded as a medical emergency [2]. Historically, GBS was synonymous with Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP). However, it is now recognized as an umbrella term that includes various clinical variants, such as axonal forms like Acute Motor Axonal Neuropathy (AMAN), as well as regional variants like Miller Fisher Syndrome (MFS). characterized by ophthalmoplegia, ataxia, as well as areflexia [3,4,5]. The first clinical accounts of the syndrome were recorded in 1859 by Landry, who documented ascending paralysis among a group of patients. Later, in 1877 and 1880, respectively, Eichorst and Leyden conducted pathologic studies that detailed inflammatory alterations in peripheral nerves [6]. In 1916, French doctors Guillain, Barre, as well as Strohl described 2 military patients who had elevated protein levels in their Cerebrospinal fluid (CSF) while maintaining normal cell counts this characteristic is now referred to as albumin cytological dissociation [7]. In 1949, Haymaker and Kernohan provided a detailed account of the histopathological findings associated with inflammatory demyelination in 50 cases of GBS that resulted in death, thereby laying the groundwork for understanding its neuropathology. In the 1950s, the autoimmune basis of the disease was further validated through animal models, as Waksman and Adams successfully induced experimental

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

allergic neuritis using nerve tissue and adjuvants. GBS is usually preceded by either a respiratory or gastrointestinal infection, with Campylobacter jejuni being the most frequently linked pathogen [8,9]. Other prior infections include cytomegalovirus, Epstein-Barr virus, as well as more recently, Zika virus [10].

About two-thirds patients report having experienced such infection in the weeks prior. The dominant hypothesis posits that molecular mimicry between microbial antigens and components of the peripheral nervous system, especially gangliosides, initiates an autoimmune response that results in demyelination or axonal damage. Antiganglioside antibodies were identified in approximately one-third of patients, corroborating this mechanism [11]. From an epidemiological standpoint, the global annual incidence of GBS is about 1-2 cases per 100,000 person-years, though this varies by region. Bangladesh shows the highest incidence (2.5 in adults and 3.25 in children per 100,000), followed by Latin America, North America, and Europe. The incidence in East Asia is the lowest, reported at 0.44–0.67 per 100,000 [12]. It is important to note that incidence of condition increases with age, climbing by 20% each decade, and that males are affected more often than females. Paediatric GBS is less common, as indicated by a Danish registry that reports a median age of 8 years and a peak incidence at age 2. Seasonality has been recorded as well, Winter peaks are noted in Western countries, whereas tropical and subtropical areas experience peaks in the summer. Clinically, GBS typically presents as a rapidly advancing symmetrical weakness of limbs, often starting in legs, as well as progressing upward (ascending paralysis). A primary characteristic is hyporeflexia or areflexia. Additionally, some patients may experience pain, paraesthesia, facial weakness, or issues with autonomic function [13]. The disease course usually consists of a progressive phase, which lasts for up to 3 to 4 weeks, followed by the plateau phase that can extend to up to several months before recovering gradually. Even though GBS is a treatable syndrome, in severe cases (up to 20 % of patients), patients fail to walk without an aid a year after onset of the syndrome, and it has been seen that even with optimal care, the mortality rate is around 5 % [14]. Diagnosis is mainly based on clinical evidence, but it still must be backed up by other supplementary studies. The studies done on nerve conduction frequently show demyelinating or axonal characteristics that align with polyradiculoneuropathy. While CSF analysis typically reveals albumin cytologic dissociation, this may not be present in early stages of disease [15]. It is essential to diagnose promptly because of risk of respiratory failure and requirement for intensive supportive care. The main approach to treating GBS is immunotherapy, particularly using Intravenous immunoglobulin (IVIg) or Plasma exchange (PE). These methods have shown decreased duration of the disease along with enhanced outcomes [16]. PE's effectiveness was initially shown in the 1980s, and IVIg's followed in the 1990s. Corticosteroid`s have not demonstrated consistent benefits, and newer treatment options are being explored, particularly for GBS linked to emerging pathogens like the Zika virus [17]. During the recovery phase of GBS, rehabilitation and physical therapy are crucial. Even after motor function improvement, numerous patients suffer from extended fatigue, which greatly affects their quality of life (QoL) [18]. While physical activity is recognized for enhancing overall health outcomes such as cardiovascular fitness, bone density, and muscle strength, it may also aid patients with peripheral neuropathy by improving nerve function and alleviating pain. Nonetheless, high-quality research assessing the effectiveness of specific exercise interventions in GBS is lacking.

II. EPIDEMIOLOGY

It was estimated that incidence of GBS annually ranges from 0.89-1.89 cases per 100,000 persons worldwide, which higher rates were observed in specific areas like parts of Asia, Latin America, as well as North America. Impact of GBS varies, influenced by factors such as age, gender, geography, and seasonal variations [19]. GBS could appear at any age, however, it exhibits bimodal distribution with incidence peaks in young adults, as well as individuals over 50, suggesting a potential susceptibility related to age and possibly linked to immune system dynamics [20]. Epidemiological research consistently indicates a greater occurrence in men, with the male-to-female ratio varying from 1.5:1 to 3:2; however, this trend may differ among populations due to genetic and environmental factors. There is considerable geographical variation in incidence rates. Seasonal trends further demonstrate the complexity of GBS's etiology [21]. In Western nations, the incidence reaches its peak during winter, which correlates with viral respiratory infections. In contrast, summer peaks are frequently noted in South Asia and Latin America, particularly linked to Campylobacter jejuni, a significant cause of AMAN subtype. Roughly two-thirds of GBS cases are associated with infections, especially gastrointestinal and respiratory ones. Post-vaccination GBS has been noted, especially after influenza vaccination, though it is uncommon, and risk estimates are as low as 2 per million doses [22]. The dynamic epidemiology of GBS, influenced by host, pathogen, and environmental factors, is underscored by these trends. Figure 1 provides a concise summary of the epidemiological characteristics of Guillain-Barre Syndrome, including its incidence, age and gender distribution, geographic and seasonal trends, and notable associations with infections and vaccinations.

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078



Fig 1 Epidemiological Overview of Guillain-Barre Syndrome (GBS), Highlighting Incidence, Demographic Patterns, Geographic and Seasonal Variations, and Associations.

III. PATHOPHYISIOLOGY

GBS is acute, immune-mediated neuropathy primarily caused by infections. The mechanism most broadly acknowledged is molecular mimicry, in which pathogens like Campylobacter jejuni, cytomegalovirus, and Mycoplasma pneumoniae produce Lipooligosaccharides (LOSs) that bear structural similarities to neural gangliosides (e.g., GM1, GD1a, GQ1b). on nerves that are peripheral [23,24]. This similarity causes the immune system to erroneously produce anti-ganglioside antibodies that target elements of peripheral nervous system [25]. Research indicates that about 70% of GBS cases occur after infections. Despite intense connection between C. jejuni infection, as well as GBS, less than one in 1,000 individuals infected with C. jejuni go on to acquire the syndrome, suggesting that susceptibility is influenced by host genetic and immunological factors [26]. Various GBS variants develop depending on the kind of antibody and its nerve target [24,27].

➢ *As an Illustration:*

- Anti-GM1, as well as anti-GD1a antibodies, are associated with AMAN, which harms motor axons, as well as neuromuscular junctions.
- Anti-GQ1b antibodies are linked to MFS, which impacts cranial nerves.
- There is a correlation between anti-GT1a antibodies and the pharyngeal-cervical-brachial variant.

➢ *Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)*

AIDP represents most common variant of GBS. It features demyelination mediated by macrophages, infiltration by lymphocytes, and injury to Schwann cells. Antibodies, notably complement-fixing IgG, attach to gangliosides on myelin and Schwann cells, particularly in regions where blood-nerve barrier is compromised (such as proximal nerve roots and distal intramuscular nerves). When complement is activated, a Membrane attack complex (MAC) is formed, which disrupts myelin and leads to failure of nerve conduction. There may also be damage to nerve terminals, as well as perisynaptic Schwann cells [28].

➢ *Acute Motor Axonal Neuropathy (AMAN)*

AMAN is frequent consequence of C. jejuni infection, characterized by an antibody-mediated assault on the motor axolemma, with a particular focus on GM1 gangliosides. IgG-induced conduction block is an early damage that could reverse if there is limited axonal degeneration. In severe instances, macrophages invade the nodes of Ranvier, leading to axonal degeneration by dislocating axons from Schwann cells. This axonal damage's severity is linked to clinical outcomes [29].

➢ *Miller Fisher syndrome (MFS)*

MFS is linked to anti-GQ1b and anti-GT1a antibodies, which primarily affect cranial nerves, especially those responsible for eye movement and bulbar functions. The autoimmune assault targets presynaptic nerve terminals and perisynaptic Schwann cells, resulting in complement activation and the formation of MAC [30,31].

For all GBS variants, the clinical manifestation and severity of the disease are dictated by the kind of ganglioside targeted and the degree of complement-mediated damage [33,34]. A central role in the pathogenesis is played by complement activation. The binding of antibodies initiates complement cascade, resulting in the formation of MACs. These MACs damage nerve membranes and cause inflammation, demyelination, and axonal injury.

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

Macrophages and other inflammatory cells penetrate nerves, playing a role in the destruction of nerve fibers [35,36]. Research on animals and human pathology corroborates the involvement of these antiganglioside antibodies, as well as complement activation, in advancement of disease. The prognosis is influenced by the extent of axonal damage, particularly that mediated by macrophages, although many patients recover [37]. Although substantial advancements have been made, the precise factors contributing to host susceptibility are still unknown. Additional studies are required to enhance the accuracy of diagnoses and treatment methods that rely on immunopathological subtypes [38]. Figure 2 outlines the immunopathogenesis of Guillain-Barre Syndrome, detailing how infections initiate molecular mimicry leading to antibody-mediated nerve damage and the development of various clinical subtypes such as AIDP, AMAN, and MFS.



Fig 2 Pathophysiological Mechanism of Guillain-Barre Syndrome (GBS) Illustrating Infection-Triggered Immune Responses, Antibody Binding, and the Resulting Subtypes and Clinical Manifestations.

IV. SYMPTOMOLOGY

GBS is marked by the quick onset of symmetrical weakness in limbs, along with tingling dysesthesias in the extremities [39,40,41]. These symptoms usually appear suddenly. As illustrated in Figure 3, Guillain-Barre Syndrome presents with a wide range of symptoms, from motor weakness and sensory changes to cranial nerve involvement and autonomic dysfunction, which may vary based on age and disease severity.

➢ *Weakness:*

In GBS, the weakness usually develops rapidly and intensifies over short periods (few hours or days). Initially, the lower extremities are affected and may progress up a body to ultimately involve legs, arms, face, as well as muscles used for breathing. Individual might initially become aware of an unforeseen challenge in terms of stair-climbing or ambulation. In rare cases, the symptoms begin in facial area, as well as progress downwards to legs, as well as feet. The majority of individuals attain the peak of their vulnerability during first-two weeks following the emergence of symptoms; in third week, 90% of those affected are at their weakest.

➢ *Sensation Changes:*

GBS can result in brain receiving abnormal sensory signals from other parts of body because of nerve damage linked to the condition. This leads to unexplained and spontaneous sensations referred to as paresthesias, which individuals may experience as tingling, sensation of insects crawling across skin (referred to formication's), as well as pain. Certain individuals suffering from GBS experience intense muscular pain in back as well as /or legs. Initially, unexplained sensations occur, including tingling in feet or hands, or pain (mainly in children), typically starting in back or legs. Children will also start to struggle with walking and

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

might decline to walk. These sensations usually fade away before onset of the significant, longer-term symptoms.

- *The Syndrome's Symptoms Can be Categorized into Three Phases:*

✓ Phase of progression, lasting a few days to four weeks,
✓ Plateau phase, characterized by persistent symptoms and lasting several days to weeks,
✓ The improvement phase, during which recovery occurs.

➢ *Pain:*

Approximately 50% of patients suffering from GBS report experiencing severe pain that occurs with the slightest movement. Pain is most often experienced in back, shoulder, girdle, as well as posterior thighs. The pain may originate from either nociceptive or neuropathic sources. In patients with AIDP, the most notable symptom is a rapidly advancing weakness of the limbs that is bilateral and relatively symmetrical. In a maximum of 90 % of AIDP patients, symptoms start in the legs and progress proximally. The progressing weakness could affect respiratory muscles, and roughly a quarter of hospitalized patients need mechanical ventilation.

➢ *Cardiovascular Manifestations*

Such as bradycardia, tachycardia, blood pressure and fluctuations may require careful observation and supportive measures to reduce the risk of hemodynamic instability and cardiac arrhythmias.

➢ *Paediatrics*

May show more acute symptoms such as cranial nerve involvement, quadriplegia, autonomic dysfunction, respiratory failure. It has been reported that respiratory failure occurs more frequently in patients who exhibit upper limb weakness, rapid symptom progression, bulbar palsy, autonomic dysfunction.

➢ *Cranial Neuropathy*

Can affect facial, oropharyngeal, and oculomotor muscles, particularly in the rarer subtypes.



Fig 3 Clinical Spectrum of Guillain-Barre Syndrome (GBS), Showing Common Symptoms Including Weakness, Pain, Sensory Disturbances, Cranial Neuropathy, Paediatric Presentations, and Cardiovascular Manifestations.

V. DIAGNOSIS

GBS diagnosis is based upon multiple neurological examinations that show a typical pattern of advancing, symmetrical muscle weakness and reduced myotatic reflexes. Auxiliary testing might be beneficial for unusual subtypes or atypical cases. All suspected patients must undergo neurophysiological investigations and lumbar puncture. Nerve conduction studies (NCS) and Electromyography can support in differentiating GBS from its look-alikes [40].

➢ *Nerve Conduction Studies (NCS)*

Demyelinating and axonal types of neuropathies can be differentiated using NCS, which employs technology to do so. Needle electromyography could assist in assessing how acute a symptom of a patient. These studies might assist in assessing additional factors in differential diagnosis, including diabetic neuropathy, or neuromuscular junction disorders.

➢ *Electrodiagnostic Tests*

Electrodiagnostic tests are to be carried out one to two weeks following the start of particular symptoms as Wallerian degeneration of both sensory, as well as motor nerve fibres takes place around the same time duration; however, numerous studies have shown that early nonspecific results can also aid in diagnosing GBS within a week after onset of symptoms [42]. Initial electrodiagnostic results in GBS

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

commonly include absence or prolonged H-reflexes, as well as F-wave latencies [43]. Sural sparing pattern is thought to be unique to GBS in comparison to other polyneuropathies. This pattern would indicate a normal sural sensory response alongside abnormal sensory responses in the upper extremities. Other results would rely on variant of GBS.

➢ *Acute Motor Axonal Neuropathy (Aman)*

AMAN typically presents with low compound muscle action potential amplitudes or motor nerves that are even in excitable; however, AMAN and NCS may reveal partial or complete motor conduction block. Phenomenon is accounted for by "reversible conduction failure" [44]. Afterwards, nerves may experience Wallerian degeneration, resulting in considerable, as well as lasting, axonal damage, or they may reverse, which is considered conduction failure [43,44]. This mechanism explains why some severely disabled AMAN patients recover very quickly. Sensory nerves would be protected in AMAN in both clinical assessments as well as electrodiagnostic evaluations.

It is more probable that acute inflammatory demyelinating polyneuropathy would exhibit characteristics such as temporal dispersion, slow conduction velocities, partial motor conduction block, prolonged distal latencies, as well as prolonged or absent F-wave latencies [45]. Acute motor and sensory axonal neuropathy (AMSAN) are characterized by sensory potentials, as well as low-amplitude motor. Miller-Fisher syndrome is normally characterized by reduced or lack of sensory nerve action potentials.

➢ *Cerebrospinal Fluid (CSF)*

CSF demonstrates typical albuminocytological dissociation pattern. This term indicates that the spinal fluid has normal white blood cell count but elevated protein level [46]. This trend, however, was only observed in 80 % patients two weeks after the onset of symptoms. Consequently, not finding this classic indicator does not rule out diagnosis. An increased white blood cell count should raise the possibility of other infectious GBS mimics, like HIV seroconversion.

Several ganglioside antibodies were associated with GBS. Included among antibodies are anti-GQ1B, anti-GM1, anti-$GD1_A$, as well as anti-$GT1_A$. These vary in sensitivity from as low as 60 % (anti-GM1 antibodies in AMAN) to above 90 % (anti-GQ1B antibodies in MFS). These lab analyses typically take some time to produce results, and as a consequence, they might not be useful for decision-making at moment of admission of patient [45,46,47].

Imaging research, including Magnetic resonance imaging (MRI) of spine, could reveal augmentation of nerve roots, suggesting inflammation-induced disruption of blood-nerve barrier in GBS. The primary benefit of MRI in GBS cases is its ability to exclude other causes of facial diplegia or quadriparesis, like transverse myelitis or intracranial disease [48].

Patients at high risk of respiratory compromise should be followed up with serial Negative Inspiratory Force (NIF). Those patients who cannot achieve a Negative Inspiratory Force (NIF) 20 to 30cm H_2O should be regarded as extremely high-risk patients [46,48]. Figure 4 illustrates the phase-wise clinical course of Guillain-Barre Syndrome, highlighting key symptoms, therapeutic interventions, and monitoring strategies from disease onset through recovery or relapse.



Fig 4 Clinical Progression and Management of Guillain-Barre Syndrome (GBS) Across Acute, Progressive, and Plateau Phases, Including Monitoring, Immunotherapy, and Supportive Care.

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

VI. TREATMENT

It is believed that Plasma Exchange (PE) works by eliminating pathogenic antibodies, complement proteins, as well as humoral mediators that contribute to progression of GBS. There are two components to treating GBS: Supportive Care and Specific Therapy.

➢ *Supportive Care*

The foundation of treatment continues to be supportive care. Most patients who progress beyond acute phase of disease will recoup function. But, progression of neuropathy can be so swift that within a day of the symptomatic onset, endotracheal intubation, as well as mechanical ventilation, may become essential. Therefore, it is necessary to admit all patients with GBS to hospital for careful monitoring of cranial nerve dysfunction, respiratory compromise, as well as autonomic instability [43,49]. Dysfunction of the autonomic nervous system can present variations in gastrointestinal pseudo-obstruction, urinary retention, blood pressure, as well as cardiac dysrhythmias.

Due to the fact that patients are often immobilized for extended periods, prophylaxis against deep venous thrombosis should be administered. With the weakening of respiratory muscles, elective endotracheal intubation ought to be taken into account. Measurable respiratory parameters can be used to predict progression to respiratory failure. Those patients who cannot show this minimal lung function need to be intubated [45]. It is essential to frequently reassess and conduct serial lung function tests for quick advancement. Further predictors of later mechanical ventilation comprise these factors:

- a duration of less than seven days between the start of GBS as well as hospitalization,
- coughing that is not effective,
- elevated liver enzyme levels,
- an inability to elevate the head or elbows off the bed, and
- an inability to stand.

Among patients with a prior assessment of vital capacity, the predictors for mechanical ventilation included the duration between the onset of GBS and admission to a hospital for a duration shorter than 7 days, an incapacity to elevate head, as well as vital capacity below 60% of what is predicted. While one of the retrospective types of research showed 40% reduction from predicted vital capacity, another study reported 60% reduction. This difference may be connected to the varying study methods, as well as greater number of patients included in subsequent study.

It is necessary to treat pain and psychological stress. Because the risk of ileus is already heightened, narcotics should be used carefully. Gentle massage, frequent position changes and passive range-of-motion exercises are all important parts of physical therapy that may help in relieving pain [34],50]. Carbamazepine (Tegretol), as well as gabapentin (Neurontin), were utilized as auxiliary treatments for pain management in GBS. Individuals receiving treatment with these medications required fewer narcotic analgesia, experienced fewer narcotic side effects, as well as slight sedation than those who received a placebo. Patients are paralysed due to illness, yet they remain mentally alert, as well as fearful. Constant reassurance, as well as talks about stages of illness, as well as recovery may help in reducing the psychological stress.

➢ *Surveillance and Control in Cases of Respiratory Failure and Airway Compromise:*

Mechanical ventilation is necessary in 20-30% GBS patients who experience neuromuscular respiratory failure. The neurologist should keep an eye out for clinical pointers of imminent respiratory failure, such as tachypnea, reliance on accessory muscles for breathing, lack of coordination between chest and abdominal movements, and tachycardia. Indications of an imminent respiratory arrest are typically vital capacity of under 20 mL/kg, maximal inspiratory pressure (PI max) below 30 cm H_2O, or maximal expiratory pressure (PE max) under 40 cm H_2O [38]. The time from onset to admission being under one-week, facial weakness, not being able to cough, not being able to raise one's head from the pillow, as well as atelectasis on a chest radiograph, are additional factors linked to respiratory failure, as well as the necessity for mechanical ventilation. Demyelinating GBS patients seem to have higher likelihood of needing mechanical ventilation. Patients with GBS who need mechanical ventilation are at significant risk of developing serious complications like pneumonia, tracheobronchitis, pulmonary embolism, or bacteraemia. Mechanical ventilation is necessary for some patients with GBS due to serious bulbar dysfunction that leads to problems with secretion clearance, raises the likelihood of aspiration, and disrupts gas exchange. For GBS, the average time spent on mechanical ventilation is 2 to 6 weeks. Once there is an enhancement in successive pulmonary function tests and strength, weaning from the ventilator should take place. In the case that pulmonary function tests show improvement after 2 weeks, it might be better to wait an additional week before attempting to wean the patient off the ventilator [49,51].

➢ *Surveillance and Control in Cases Autonomic Nervous System Dysfunction:*

In most patients with GBS, acute autonomic dysfunction arises, and it constitutes a major factor contributing to mortality in this population. Hemodynamic and Cardiac disorders are most severe, as well as common problems, but GBS patients also often suffer from dysautonomia, which affects gastrointestinal, as well as bladder function. Sympathetic overactivity combined with parasympathetic underactivity is most prevalent pattern of autonomic outflow imbalance; however, other patterns can occur as well, even during disease course of individual patient. In extreme cases of GBS, severe dysautonomia is most commonly observed when a patient reaches their lowest clinical level, including those in ventilated intensive care. On the contrary, it can also occur at early stages of disease and might resolve during the peak of paralysis episodes.

Most GBS patients experience cardiac, as well as hemodynamic disturbances, which appear as hypertension, postural hypotension, as well as tachycardia. It is strongly

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

advised to monitor blood pressure, as well as heart rate, for at least the cases that are severely affected, and it should be taken into account for less severe cases. Cardiovascular monitoring should persist until the patient shows signs of clinical improvement or, in cases where ventilation was necessary, until ventilatory support has been fully withdrawn. Heart rate, as well as blood pressure disturbances, should not be presumed to result from autonomic neuropathy, especially if they are sustained or if patient has mild GBS otherwise. It is important to take into account electrolyte disturbance, undertreated pain, dehydration, pulmonary embolus, and sepsis [50,52].

In GBS, the most frequently observed sign of dysautonomia is sinus tachycardia. Tachycardia, typically ranging from 100-120 beats per min, holds little clinical significance. Presence of tachycardia, however, indicates that a GBS patient has cardiac dysrhythmia, as well as may also identify patients who are at greater risk for serious bradycardia, heart block, as well as asystole. Cases of heart block, asystole, as well as severe bradycardia that require resuscitation, as well as cardiac pacemaker insertion, are rare. Bradycardia and asystole may be triggered by endotracheal suction and medication. Before endotracheal suction, hyperoxygenation reduces effects of severe bradycardia. About one-third of GBS patients experience hypertension. Hypertension is commonly paroxysmal, but it can also be sustained [48].

There can be considerable variations in systolic blood pressure. Hypertensive episodes can be succeeded by hypotension or, in some cases, abrupt death. In most instances, though, the hypertension is mild and temporary, so specific treatment is usually unnecessary, especially since some GBS patients experience labile hypertension with low blood pressure occurring after high blood pressure. In cases of severe, as well as sustained, hypertension, specific treatment may be required. In these situations, it is advisable to consider short-acting antihypertensives that allow for titration. As many as one-third of patients with GBS experience postural and episodic hypotension. To reduce risk of hypotension, it is crucial to maintain intravascular volume, as well as avoid diuretics as well as other medications that reduce blood pressure whenever feasible. Patients with GBS who are at risk for hypotension must not be left alone while seated [53].

In up to one-third of patients, Urinary retention may occur. In GBS patients who are not ambulatory, as well as require bladder dysfunction is especially prevalent. ventilation using mechanical means. Urinary retention is probably a result of dysfunction in the sacral parasympathetic, as well as pudendal motor nerves. It can be managed using sterile, closed urinary drainage system. 15% of patients with severe GBS show gastrointestinal motility disorders. Signs of upper gastrointestinal ileus can include abdominal distention, pain, and cramping. Constipation can be a manifestation of lower gastrointestinal ileus.

Ileus can develop either during acute phase of deteriorating motor strength or later on during plateau or recovery phases. When ileus happens during acute phase of GBS, it typically occurs alongside other signs of dysautonomia. It is believed to result from autoimmune damage to parasympathetic vagal nerve affecting small intestine, stomach, as well as most of colon, as well as sacral parasympathetic nerves impacting the distal colon [49]. Later phases of Ileus of GBS are linked to extended periods of immobility and mechanical ventilation, rather than to other dysautonomias. Ileus is usually temporary, but it can last for days or even weeks.

Regular inspection of abdomen, encompassing abdominal girth measurement, auscultation, as well as abdominal radiography, is occasionally the norm for people with GBS, especially people with additional dysautonomias, as well as those who need mechanical ventilation. Nasogastric suctioning, suspending enteral feeds, and using erythromycin or neostigmine may effectively help manage dysmotility. If ileus continues for over a few days, parenteral nutrition might be required. Occasionally, rectal tubes are utilized. Avoiding narcotics when possible is also beneficial for reducing dysmotility [54].

- *Prophylaxis for Deep Vein Thrombosis (DVT)*

The immobilization resulting from GBS increases the risk of developing DVT and pulmonary embolism. For individuals with walking disability, fractionated or unfractionated heparin administered subcutaneously, as well as support stockings, are advised for GBS patients until they can walk on their own. The basis for these recommendations is evidence that subcutaneous heparin (5000U every 12hrs) or enoxaparin (40mg daily) lowers risk of DVT in acutely ill patients, as well as urological and orthopaedic surgical patients, along with proof that support stockings also minimize DVT risk.

The majority of GBS patients report pain, which ought to be handled aggressively. In a prospective GBS patient study, 47% reported pain that had been ‘‘horrible,’’ ‘‘excruciating’’ or ‘‘distressing’’. Also, most common are sharp aching back as well as lower extremity pain, as well as dysesthetic pain. There is very less evidence present to prove the correlation between the intensity of pain and degree of disability. 75% of GBS patients in this study received oral or parenteral opioid analgesics, while 30% received intravenous morphine infusions (ranging from 1-7mg/h). Close monitoring is recommended as narcotics can worsen GI dysmotility and bladder distention.

Gabapentin (e.g., 15mg/kg/d), as well as carbamazepine (e.g., 300mg daily), are said to be useful in helping GBS patients feel less pain. Other short as well as long-term management of neuropathic pain, adjuvant therapy (such as tramadol, mexiletine, tricyclic antidepressant medications) might also be beneficial. As first-line treatment, acetaminophen or nonsteroidal anti-inflammatory agents can also be administered, but they lack effectiveness [55].

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

VII. PROBLEMS AFTER ACUTE CARE HOSPITALIZATION FOR PATIENTS WITH GUILLAIN-BARRE SYNDROME

➢ *In-Patient Rehabilitation:*

Roughly 40% of GBS patients who are hospitalized will require inpatient rehabilitation. These patients, along with those who needed mechanical ventilation and other signs of greater severity, GBS may require an extended rehabilitation stay. Management of rehabilitation strategies for GBS patients was derived from experiences in the management of GBS patients during their acute care hospitalization and various other neuromuscular diseases. The problems that arise from an inpatient rehabilitation stay are similar to those from the hospital stay.

For example, patients with GBS after inpatient hospitalization are likely to still face an elevated risk of complications resulting from weakness, as well as immobilization (such as DVT, postural hypotension, decubitus ulcer,), sensory loss (like compression neuropathy), dysautonomia (such as bladder overdistention), restrictive pulmonary function (e.g., sleep hypercapnia as well as hypoxia, pneumonia), weight reduction (e.g., compression neuropathy, decubitus ulcer), as well as psychosocial issues (e.g., depression) [53,54]. Daily range-of-motion exercises may help prevent complications such as muscle shortening and joint contractures, which can be associated with muscle weakness. During rehabilitation, suitable exercise routines are employed to enhance strength. Exercise plans should refrain from overexerting muscle groups, as this has been linked to paradoxical weakness and hinders recovery [56]. To optimize motor function, orthotics should be recommended. Patients who suffer from severe proprioceptive loss and ataxia should receive therapy that encompasses sensory reintegration techniques and coordination-enhancing repetitive exercises.

VIII. SPECIFIC THERAPY

➢ *Immunotherapy*

If administered in the initial weeks of disease, PE, as well as IVIg are effective immunotherapies for both adults, as well as paediatric patients with GBS. In patients with GBS, PE is typically given as 1 plasma volume (50mL/kg) on 5 different occasions for 1-2 weeks. For patients with GBS, both adults and children, the typical administration of IVIg involves a total of 2g/kg spread out for 2-5 days. In 2003, American Academy of Neurology (AAN) Quality Standards Subcommittee determined that for GBS patients needing walking assistance, starting IVIg within two weeks of onset yields the same effectiveness in accelerating recovery [57].

The Quality Standard Subcommittee advises IVIg treatment for GBS patients needing walking assistance within two weeks (level A recommendation) or four weeks (level B recommendation) of neuropathic symptom onset. When determining whether to use PE or IVIg, various factors should be considered. These include the treatments' availability and side effect profiles, as they relate to the patient's condition, as well as comorbidities. In key studies that compared IVIg with PE, incidence of complications has been somewhat higher in PE group than in IVIg group. Major negative incidents linked to PE comprise hypotension, pneumonia, septicemia, abnormal clotting, complications arising from central venous access, as well as hypocalcemia. Citrate that is infused for anticoagulation or included in fresh-frozen plasma can result in metabolic acidosis or hypocalcemia [60].

Paresthesias and muscle cramps are symptoms of hypocalcemia, as well as cardiac arrhythmias in severe cases. PE is contraindicated in cases of significant hemostatic disorders, active infection, unstable cardiovascular status, and pregnancy. Major negative occurrences linked to IVIg comprise renal failure, meningism's, myocardial infarction, and vomiting. IVIg can be used during pregnancy. As a rule, IVIg side effects are typically not serious and happen in fewer than 10% of patients. To prevent fluid overload, patients with congestive heart failure or coronary artery disease are advised to use a slow infusion rate. IVIg raises serum viscosity, which could elevate risk of thromboembolic events. IVIg might be considered relatively contraindicated for patients with elevated serum viscosity (for e.g., that caused by serum cryoglobulins), hypergammaglobulinemia or high triglycerides.

It`s use in patients with recent Deep vein thrombosis (DVT) should also be approached with caution. Acute tubular necrosis is uncommon in patients who already have kidney disease, particularly among diabetics, the elderly and those with inadequate hydration. The most prevalent is the link between acute tubular necrosis and IVIg products containing high sucrose concentrations. Close monitoring of BUN (blood urea nitrogen), as well as creatinine levels, is crucial, as well as proper hydration during IVIg treatment must be ensured, mainly for patients at risk of renal tubular necrosis. Risk can be reduced by choosing products with low osmolality, IVIg preparation dilution and administering at a slower rate of infusion. Treatment of GBS with corticosteroids does not work. There is no significant benefit or harm from using intravenous methylprednisolone alone [61]. IV methylprednisolone (e.g., 500mg daily for 5days, given in a course of 48 hours) in conjunction with IVIg of the initial IVIg dose) can speed up recovery, but it seems not to have a major impact on the long-term outcome. Immunoabsorption therapy offers a substitute to PE that avoids the use of human blood products as replacement fluids, thus minimizing the risk of infection or allergic reactions. Due to the reduced loss of albumin, immunoadsorption therapy eliminates Ig from circulation without requiring fresh frozen plasma or albumin replacement [58].

For example, certain patients who were first diagnosed with GBS, having had a preceding infection, an abrupt onset of neuropathic symptoms within a month, are later re-diagnosed with CIDP due to persistence of neuropathy deficits resulting from current demyelination caused by active autoimmune process. It can be difficult at times to ascertain if persistent deficits result from current demyelination and autoimmunity or from secondary, residual axonal damage of formerly active GBS. It can be useful to carry out electrodiagnostic testing again in such cases. If the results

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

indicate that demyelination is still occurring, consideration should be given to CIDP and to treating CIDP (e.g., with corticosteroids) [62].

MFS patients who do not receive treatment usually achieve full recovery within a few months. Patients suffering from MFS or one of its variants (such as BBE) are often administered immunotherapy (like PE or IVIg). Patients who have more severe or complex form of anti-GQ1b antibody syndrome, including those with BBE or overlapping GBS, should likely receive immunotherapy.

IX. CONCLUSION

GBS is a multifaceted neurological disorder characterized by various clinical manifestations and driven by immune-mediated pathology. It presents a challenge to clinicians due to its swift advancement and the possibility of severe complications, being a post-infectious condition that mainly affects the peripheral nervous system. Although GBS is rare, its diverse range of subtypes—such as AIDP, AMAN, AMSAN, and MFS—requires a tailored and detailed approach to diagnosis, treatment, and recovery planning.

The causes of GBS are varied, but there is considerable evidence that molecular mimicry is a key mechanism. Infections, particularly with Campylobacter jejuni, as well as viruses, including Epstein-Barr virus, Zika virus, as well as cytomegalovirus, can induce autoimmune responses that attack elements of peripheral nerves. Demyelination or axonal degeneration may occur due to this immune dysregulation, resulting in the characteristic symptoms of progressive symmetrical weakness, sensory abnormalities, and areflexia. Variety of presentations as well as variants underscores necessity of thorough clinical evaluation as well as supplementary diagnostic methods, including CSF analysis and electrophysiological studies.

Managing GBS requires both immunotherapy and supportive care. The principal treatments are IVIg, as well as PE, both of which were shown to lessen the severity and duration of the disease. To achieve maximum effectiveness, these interventions should be timely and ideally launched within two weeks following the onset of symptoms. Once considered, corticosteroids have not demonstrated consistent benefits and are no longer part of standard treatment. Given the risk of autonomic instability, respiratory failure, and prolonged immobilization, supportive care is especially vital. Careful observation of respiratory function is crucial, given that mechanical ventilation may be necessary for as many as 25% of patients admitted to the hospital. Indicators like diminishing vital capacity, failure to elevate the head, and unproductive cough assist in forecasting respiratory compromise.

The long-term recovery from GBS shows a high degree of variability. Although a significant number of patients show major neurological improvement within a few months, as many as 20% still suffer from disabling symptoms one year after onset. Quality of life can be greatly impacted by lingering weakness, pain, and fatigue. In this context, thorough rehabilitation takes on great importance. Neuromuscular reconditioning and functional recovery can be supported by multidisciplinary rehabilitation programs that include physical and occupational therapy. Furthermore, DVT prophylaxis, pain management, and psychological support are crucial during the plateau and recovery phases.

Insights from epidemiology enrich our comprehension of GBS. With age, the incidence rises, and there are consistent reports of a male predominance. The influence of environmental and infectious triggers is underscored by geographic and seasonal trends, including the higher incidence in summer in South Asia and the winter peaks observed in Western countries. While GBS related to vaccination is still a worry, it occurs at an extremely rare rate, which strengthens the case for the overall safety of immunization programs.

On conclusion, GBS constitutes a medical emergency that requires prompt diagnosis and assertive treatment. While there have been major advancements in immunotherapy and critical care that have led to enhanced survival rates, much effort is still needed to enhance functional outcomes and avert long-term disability. A more profound comprehension of its immunopathogenesis, the discovery of prognostic biomarkers, and the creation of targeted therapies could transform the treatment landscape. Until that time, the best way to manage and rehabilitate those impacted by this intricate neurological condition is still a proactive, patient-centred, and interdisciplinary approach.

REFERENCES

[1]. Dhuli K, Naureen Z, Medori MC, Fioretti F, Caruso P, Perrone MA, Nodari S, Manganotti P, Xhufi S, Bushati M, Bozo D. Physical activity for health. Journal of preventive medicine and hygiene. 2022 Oct 17;63(2 Suppl 3): E150.

[2]. Mingsheng LI, Liying CU. The changes in European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Chinese Journal of Neurology. 2022:181-6.

[3]. Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nature Reviews Neurology. 2014 Aug;10(8):469-82.

[4]. Hadhiah K, Alhashim A, Al-Dandan HA, Alhassan E, Alqarni AM, Memish AA, Alabdali M. Guillain–Barré syndrome post-SARS-CoV-2 vaccine: a systematic review and data analysis on its clinical, laboratory, electrophysiological, and radiological features. Frontiers in Neurology. 2024 Jan 29; 15:1332364.

[5]. Laman JD, Huizinga R, Boons GJ, Jacobs BC. Guillain-Barré syndrome: expanding the concept of molecular mimicry. Trends in immunology. 2022 Apr 1;43(4):296-308.

[6]. Prineas JW. Pathology of the Guillain-Barré syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1981;9(S1):6-19.

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

[7]. Haymaker W, KEBNOHAN JW. The Landry-Guillain-Barré syndrome: a clinicopathologic report of fifty fatal cases and a critique of the literature. Medicine. 1949 Feb 1;28(1):59.
[8]. Wachira VK, Peixoto HM, de Oliveira MRF. Systematic review of factors associated with the development of Guillain-Barre Syndrome 2007–2017: what has changed? Trop Med Int Health 2019; 24: 132–42.
[9]. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA 2004;101: 11404–09.
[10]. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia:a case-control study. Lancet 2016; 387: 1531–39.
[11]. Alter M. The epidemiology of Guillain-Barré syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1990;27(S1): S7-12.
[12]. Madden J, Spadaro A, Koyfman A, Long B. High risk and low prevalence diseases: Guillain-Barré syndrome. The American Journal of Emergency Medicine. 2024 Jan 1; 75:90-7.
[13]. Nguyen, T.P.; Taylor, R.S. Guillain-Barre Syndrome. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2023.
[14]. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123–33.
[15]. Dobson JL, McMillan J, Li L. Benefits of exercise intervention in reducing neuropathic pain. Frontiers in cellular neuroscience. 2014 Apr 4; 8:102.
[16]. Simatos Arsenault N, Vincent PO, Yu BH, Bastien R, Sweeney A. Influence of exercise on patients with Guillain-Barré syndrome: a systematic review. Physiotherapy Canada. 2016;68(4):367-76.
[17]. Levin KH. Variants and mimics of Guillain Barré syndrome. The Neurologist. 2004 Mar 1;10(2):61-74.
[18]. Kiper P, Chevrot M, Godart J, Cieślik B, Kiper A, Regazzetti M, Meroni R. Physical Exercise in Guillain-Barré Syndrome: A Scoping Review. Journal of Clinical Medicine. 2025 Apr 12;14(8):2655.
[19]. Elendu C, Osamuyi EI, Afolayan IA, Opara NC, Chinedu-Anunaso NA, Okoro CB, Nwankwo AU, Ezidiegwu DO, Anunaso CA, Ogbu CC, Aghahowa SO. Clinical presentation and symptomatology of Guillain-Barré syndrome: A literature review. Medicine. 2024 Jul 26;103(30): e38890.
[20]. Walling AD, Dickson G. Guillain-barré syndrome. American family physician. 2013 Feb 1;87(3):191-7.
[21]. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology. 2008 Oct 1;7(10):939-50.
[22]. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-barré syndrome. The lancet. 2021 Mar 27;397(10280):1214-28.
[23]. Oomes PG, Jacobs BC, Hazenberg MP, Bänffer JR, van der Meché FG. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Annals of neurology. 1995 Aug;38(2):170-5.
[24]. Sheikh KA, Nachamkin I, Ho TW, Willison HJ, Veitch J, Ung H, Nicholson M, Li CY, Wu HS, Shen BQ, Cornblath DR. Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: molecular mimicry and host susceptibility. Neurology. 1998 Aug;51(2):371-8.
[25]. Visser LH, Van der Meché FG, Meulstee J, Rothbarth P, Jacobs BC, Schmitz PI, Van Doorn PA. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology. 1996 Sep;47(3):668-73.
[26]. Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM. Serum antibodies to gangliosides in Guillain-Barré syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1988 May;23(5):440-7.
[27]. Hafer-Macko C, Hsieh ST, Ho TW, Sheikh K, Cornblath DR, Li CY, McKhann GM, Asbury AK, Griffin JW. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1996 Oct;40(4):635-44.
[28]. Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. Journal of neurocytology. 1996 Jan; 25:33-51.
[29]. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1992 Jun;31(6):677-9.
[30]. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993 Oct;43(10):1911
[31]. Rahman RS, Bauthman MS, Alanazi AM, Alsillah NN, Alanazi ZM, Almuhaysin MI, Almutairi RK, Binobaid KS, Alharthi YH, Bawareth RM, Alrawili ON. Guillain–Barré syndrome: pathophysiology, etiology, causes, and treatment. International Journal of Community Medicine and Public Health. 2021 Jul;8(7):3624.
[32]. Yuki, N., Yamada, M., Koga, M., Odaka, M., Susuki, K., Tagawa, Y., Ueda, S., Kasama, T., Ohnishi, A., Hayashi, S. and Takahashi, H., 2001. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Annals of Neurology: Official Journal of the American

ISSN No: 2456-2165 https://doi.org/10.38124/ijisrt/25jun078

Neurological Association and the Child Neurology Society, 49(6), pp.712-720.
[33]. Burns TM. Guillain-barré syndrome. InSeminars in neurology 2008 Apr (Vol. 28, No. 02, pp. 152-167). © Thieme Medical Publishers.
[34]. Jacobs BC, Rothbarth PH, Van der Meché FG, Herbrink P, Schmitz PI, De Klerk MA, Van Doorn PA. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998 Oct;51(4):1110-5.
[35]. Susuki K, Nishimoto Y, Yamada M, Baba M, Ueda S, Hirata K, Yuki N. Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Annals of neurology. 2003 Sep;54(3):383-8.
[36]. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K. Animal model of axonal Guillain-Barre Syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001 Jun;49(6):712-20.
[37]. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993 Oct;43(10):1911-7 Willison HJ, O'Hanlon G, Paterson G, O'Leary CP, Veitch J, Wilson G, Roberts M, Tang T, Vincent A. Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain-Barré syndrome. J Infect Dis. 1997 Dec;176 Suppl 2: S144-9.
[38]. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992 Jun;31(6):677-9.
[39]. Cosi V, Versino M. Guillain-barre syndrome. Neurological Sciences. 2006 Mar; 27:47-51.
[40]. https://www.ninds.nih.gov/health-information/disorders/guillain-barre-syndrome
[41]. https://my.clevelandclinic.org/health/diseases/15838-guillain-barre-syndrome
[42]. Newswanger DL, Warren CR. Guillain-Barré syndrome. American family physician. 2004 May 15;69(10):2405-10.
[43]. Ropper AH. The Guillain–Barré syndrome. New England journal of medicine. 1992 Apr 23;326(17):1130-6
[44]. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1990;27(S1): S21-4.
[45]. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Archives of neurology. 2001 Jun 1;58(6):913-7.
[46]. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001 Apr 24;56(8):1104-6.
[47]. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain–Barré syndrome. New England Journal of Medicine. 1995 Nov 23;333(21):1374-9.
[48]. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT. The Guillain–Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. New England Journal of Medicine. 1998 Dec 17;339(25):1797-802.
[49]. Hahn AF. Guillain-barré syndrome. The lancet. 1998 Aug 22;352(9128):635-41.
[50]. Lindenbaum Y, Kissel JT, Mendell JR. Treatment approaches for Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Neurologic clinics. 2001 Feb 1;19(1):187-204.
[51]. Sharshar T, Chevret S, Bourdain F, Raphaël JC, French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Early predictors of mechanical ventilation in Guillain-Barré syndrome. Critical care medicine. 2003 Jan 1;31(1):278-83.
[52]. Sater RA, Rostami A. Treatment of Guillain-Barre Syndrome with intravenous immunoglobulin. Neurology. 1998 Dec;51(6_suppl_5): S9-15.
[53]. Hughes RA, Swan AV, Van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. 2014(9).
[54]. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005 Jul 1;116(1):8-14.
[55]. French Cooperative Group on Plasma Exchange in Guillain-Barrk Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Annals of neurology. 1987 Dec;22(6):753-61.
[56]. Guillain-Barré Syndrome Study Group*. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985 Aug;35(8):1096-.
[57]. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996 Jan;46(1):100-3.
[58]. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA, Guillain-Barré Syndrome Study Group. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Annals of neurology. 1988 Apr;23(4):347-53.
[59]. Thornton CA. Safety of intravenous immunoglobulin. Archives of Neurology. 1993 Feb 1;50(2):135-6.
[60]. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007 Apr 3;68(14):1144-6.
[61]. McLeod JG. Invited review: autonomic dysfunction in peripheral nerve disease. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 1992 Jan;15(1):3-13.
[62]. Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. 2017(2).